1988
On the value of response criteria in therapeutic research.
Devita V. On the value of response criteria in therapeutic research. Bulletin Du Cancer 1988, 75: 863-9. PMID: 3061500.Peer-Reviewed Original ResearchConceptsLocal tumor presentationPrimary chemotherapyTumor presentationBiological marker of responseResponse to primary chemotherapySmall-cell lung cancerDiffuse large-cell lymphomaResponse criteriaLarge-cell lymphomaComplete remission rateRelapse-free survivalFull dose chemotherapyPrimary tumor massMarkers of responseCytoreductive effectInduction chemotherapyDose chemotherapyRemission ratePediatric malignanciesTumor massPrimary treatmentChemotherapyLung cancerInduction cyclesAlternative therapies
1984
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Bakemeier R, Anderson J, Costello W, Rosner G, Horton J, Glick J, Hines J, Berard C, DeVita V. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Annals Of Internal Medicine 1984, 101: 447-56. PMID: 6089632, DOI: 10.7326/0003-4819-101-4-447.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCarmustineClinical Trials as TopicCombined Modality TherapyCyclophosphamideFemaleGastrointestinal DiseasesHematologic DiseasesHodgkin DiseaseHumansMaleMechlorethamineNeoplasm StagingPeripheral Nervous System DiseasesPrednisoneProcarbazineRandom AllocationVinblastineVincristineConceptsAdvanced Hodgkin's diseaseHodgkin's diseaseUntreated patientsEastern Cooperative Oncology Group studyDuration of complete remissionRandomized prospective studyTreatment of patientsMOPP regimenHematologic toxicityInduction chemotherapyComplete remissionChemotherapy regimensRemission rateNeurological toxicityProspective studyMOPPRemissionTherapeutic benefitChemotherapyPatientsInduction phaseDiseaseToxicityGroup studyDuration
1983
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher R, DeVita V, Hubbard S, Longo D, Wesley R, Chabner B, Young R. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Annals Of Internal Medicine 1983, 98: 304-9. PMID: 6600902, DOI: 10.7326/0003-4819-98-3-304.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationEtoposideFemaleHumansLeucovorinLeukopeniaLymphomaMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazineVincristineConceptsComplete remission rateDiffuse aggressive lymphomasMOPP chemotherapyRemission rateAggressive lymphomaDose-limiting toxicityRelapse-free survivalNew treatment programPhases of treatmentComplete remissionComplete respondersMedian durationMedian survivalUntreated patientsTumor responsePatient rateLate intensificationPatientsAdvanced stageChemotherapyTreatment programSurvivalLymphoma
1979
A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non‐Hodgkin's lymphoma
Brereton H, Young R, Longo D, Kirkland L, Berard C, Jaffe E, Devita V, Johnson R. A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non‐Hodgkin's lymphoma. Cancer 1979, 43: 2227-2231. PMID: 378350, DOI: 10.1002/1097-0142(197906)43:6<2227::aid-cncr2820430611>3.0.co;2-j.Peer-Reviewed Original Research
1977
Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.
Young R, Johnson R, Canellos G, Chabner B, Brereton H, Berard C, DeVita V. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Journal Of The National Cancer Institute 1977, 61: 1153-9. PMID: 332349.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood PlateletsClinical Trials as TopicCyclophosphamideDrug Therapy, CombinationFemaleHumansLeukocytesLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm StagingPrednisoneProcarbazineProspective StudiesRadiation DosageRadiation InjuriesRemission, SpontaneousTime FactorsVincristineConceptsHigher overall response rateCyclic combination chemotherapyOverall response rateCombination chemotherapyMedian followupResponse rateSimilar complete remission ratesRelapse-free survival rateComparison of chemotherapyMonths median followupComplete remission rateOverall median survivalDisease-free survivalTotal body irradiationNodular mixed lymphomaInduction regimenInduction therapyComplete remissionMedian survivalProspective trialRemission rateUntreated patientsMixed lymphomaMalignant lymphomaNodular lymphoma
1975
Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma.
Young R, Chabner B, Hubbard S, Canellos G, DeVita V. Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma. National Cancer Institute Monograph 1975, 42: 145-8. PMID: 825777.Peer-Reviewed Original ResearchConceptsAdvanced ovarian carcinomaOvarian carcinomaHigher overall response rateOral alkylating agentTrials of chemotherapyOverall response ratePAM therapyNational Cancer InstituteIntravenous cyclophosphamideSystemic chemotherapyRemission rateCombination therapyProspective trialsHigh-doseTherapeutic efficacyConventional treatmentResponse rateCancer InstituteChemotherapyAlkylating agentsCarcinomaTherapyTrialsCyclophosphamideMelphalan
1972
A decade of combination chemotherapy of advanced Hodgkin's disease
Devita V, Canellos G, Moxley J. A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer 1972, 30: 1495-1504. PMID: 4565815, DOI: 10.1002/1097-0142(197212)30:6<1495::aid-cncr2820300613>3.0.co;2-i.Peer-Reviewed Original ResearchConceptsAdvanced Hodgkin's diseaseComplete remission rateHodgkin's diseaseRemission rateRemission durationCombination chemotherapySingle agentLonger disease-free intervalDisease-free intervalAcute childhood leukemiaNew treatment programCombination of drugsComplete remissionComplete respondersCooperative trialsStage IIIChildhood leukemiaEffective drugsTreatment programTherapyUse of combinationsDiseasePilot studyFurther treatmentRemissionHodgkin's Disease Therapeutic Program
DeVita V. Hodgkin's Disease Therapeutic Program. JAMA 1972, 222: 1171-1171. PMID: 4678060, DOI: 10.1001/jama.1972.03210090051025.Peer-Reviewed Original ResearchConceptsCombination of drugsRemission durationHodgkin's diseaseCombinations of effective drugsProlongation of remission durationAdvanced Hodgkin's diseaseComplete remission rateAcute childhood leukemiaRemission rateProcarbazine hydrochlorideRate of inductionCooperative trialsEffective drugsChildhood leukemiaRemissionTherapyDrugPilot studyDiseaseHodgkinDurationMOPPProcarbazineMethotrexateLeukemiaCombination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy
Canellos G, Young R, DeVita V. Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy. Clinical Pharmacology & Therapeutics 1972, 13: 750-754. PMID: 5053816, DOI: 10.1002/cpt1972135part1750.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseCombination chemotherapyProlonged disease-free intervalExtensive radiation therapyAdvanced Hodgkin's diseaseDisease-free intervalEnd of radiotherapyOnset of chemotherapyCombination chemotherapy programsDegree of myelosuppressionExtensive radiotherapyIntensive radiotherapyCurative intentComplete remissionExtensive diseasePrevious radiotherapyRemission rateChemotherapy programRadiation therapyDrug toxicityPatientsRadiotherapyMonthly cyclesChemotherapyDisease